GBA3

Summary

GBA3 (glucosylceramidase beta 3 (gene/pseudogene), HGNC:19069) is a protein-coding gene on chromosome 4p15.2, encoding Cytosolic beta-glucosidase (Q9H227). Neutral cytosolic beta-glycosidase with a broad substrate specificity that could play a role in the catabolism of glycosylceramides.

The protein encoded by this gene is a cytosolic enzyme that can hydrolyze several types of glycosides. The enzyme has its highest activity at neutral pH and is predominantly expressed in human liver, kidney, intestine, and spleen. This gene is a polymorphic pseudogene, with the most common allele being the functional allele that encodes the full-length protein. Some individuals contain a single nucleotide polymorphism that results in a premature stop codon in the coding region, and therefore this allele is pseudogenic due to the failure to produce a functional full-length protein. Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 57733 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 76 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19069
Approved symbol	GBA3
Name	glucosylceramidase beta 3 (gene/pseudogene)
Location	4p15.2
Locus type	gene with protein product
Status	Approved
Aliases	GLUC, KLrP, CBGL1
Ensembl gene	ENSG00000249948
Ensembl biotype	protein_coding
OMIM	606619
Entrez	57733

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding_LoF, 2 protein_coding_CDS_not_defined

ENST00000503442, ENST00000504802, ENST00000508166, ENST00000508264, ENST00000511446

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000503442 — 3 exons

Exon	Start	End
ENSE00002048286	22692925	22693073
ENSE00002079285	22818721	22819575
ENSE00003503716	22735981	22736208

Expression profiles

Bgee: expression breadth ubiquitous, 130 present calls, max score 99.77.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.0484 / max 558.3957, expressed in 43 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
47083	0.4864	32
47084	0.2873	27
47082	0.1194	14
47085	0.0594	14
47088	0.0487	6
47086	0.0430	14
47081	0.0041	2

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	99.77	gold quality
ileal mucosa	UBERON:0000331	97.64	gold quality
duodenum	UBERON:0002114	95.30	gold quality
adult mammalian kidney	UBERON:0000082	94.46	gold quality
liver	UBERON:0002107	94.26	gold quality
right lobe of liver	UBERON:0001114	93.89	gold quality
renal medulla	UBERON:0000362	93.47	gold quality
adult organism	UBERON:0007023	92.21	gold quality
kidney	UBERON:0002113	88.92	gold quality
nephron tubule	UBERON:0001231	87.08	gold quality
small intestine Peyer’s patch	UBERON:0003454	86.65	gold quality
small intestine	UBERON:0002108	86.64	gold quality
kidney epithelium	UBERON:0004819	85.52	gold quality
buccal mucosa cell	CL:0002336	83.39	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.28	gold quality
gall bladder	UBERON:0002110	81.93	gold quality
jejunum	UBERON:0002115	81.37	gold quality
colonic mucosa	UBERON:0000317	81.03	gold quality
metanephros cortex	UBERON:0010533	81.02	gold quality
mucosa of transverse colon	UBERON:0004991	80.57	gold quality
cortex of kidney	UBERON:0001225	80.43	gold quality
mucosa of sigmoid colon	UBERON:0004993	78.44	gold quality
renal glomerulus	UBERON:0000074	77.35	gold quality
metanephric glomerulus	UBERON:0004736	76.94	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.15	gold quality
metanephros	UBERON:0000081	74.84	gold quality
right uterine tube	UBERON:0001302	72.32	gold quality
spleen	UBERON:0002106	72.02	gold quality
rectum	UBERON:0001052	69.59	gold quality
transverse colon	UBERON:0001157	69.37	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	17.16
E-ANND-3	yes	9.36

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 7)

• The positioning of a substrate molecule (quercetin-4’-glucoside) by homology modelling revealed that hydrophobic interactions dominate the binding of the aglycone moiety. (PMID:17555766)
• The crystal structure of a covalent intermediate of the KLrP mutant E165Q, in which glucose was covalently bound to a nucleophile, Glu(373), is reported. (PMID:18662675)
• No correlation was observed between GBA3 1368A/T haplotypes and severity of type 1 Gaucher disease manifestation (PMID:20728381)
• cytosolic GBA3 is likely involved in the catabolism of cytosolic sialyl free N-glycans, possibly by stabilizing the activity of the NEU2 protein (PMID:26193330)
• Decreased expression of GBA3 correlates with a poor prognosis in hepatocellular carcinoma patients. (PMID:32412773)
• GBA3: a polymorphic pseudogene in humans that experienced repeated gene loss during mammalian evolution. (PMID:32665690)
• GBA3 promotes fatty acid oxidation and alleviates non-alcoholic fatty liver by increasing CPT2 transcription. (PMID:38428407)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gba3	ENSDARG00000031150
rattus_norvegicus	Gba3	ENSRNOG00000024634
drosophila_melanogaster	CG9701	FBGN0036659
caenorhabditis_elegans		WBGENE00016848
caenorhabditis_elegans		WBGENE00017103

Paralogs (4): LCT (ENSG00000115850), KL (ENSG00000133116), KLB (ENSG00000134962), LCTL (ENSG00000188501)

Protein

Protein identifiers

Cytosolic beta-glucosidase — Q9H227 (reviewed: Q9H227)

Alternative names: Cytosolic beta-glucosidase-like protein 1, Cytosolic galactosylceramidase, Cytosolic glucosylceramidase, Cytosolic glycosylceramidase, Glucosidase beta acid 3, Glucosylceramidase beta 3, Klotho-related protein

All UniProt accessions (0):

UniProt curated annotations — full annotation on UniProt →

Function. Neutral cytosolic beta-glycosidase with a broad substrate specificity that could play a role in the catabolism of glycosylceramides. Has a significant glucosylceramidase activity in vitro. However, that activity is relatively low and its significance in vivo is not clear. Hydrolyzes galactosylceramides/GalCers, glucosylsphingosines/GlcSphs and galactosylsphingosines/GalSphs. However, the in vivo relevance of these activities is unclear. It can also hydrolyze a broad variety of dietary glycosides including phytoestrogens, flavonols, flavones, flavanones and cyanogens in vitro and could therefore play a role in the metabolism of xenobiotics. Possesses transxylosylase activity in vitro using xylosylated ceramides/XylCers (such as beta-D-xylosyl-(1<->1’)-N-acylsphing-4-enine) as xylosyl donors and cholesterol as acceptor. Could also play a role in the catabolism of cytosolic sialyl free N-glycans.

Subunit / interactions. May interact with NEU2.

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Present in small intestine (at protein level). Expressed in liver, small intestine, colon, spleen and kidney. Down-regulated in renal cell carcinomas and hepatocellular carcinomas.

Post-translational modifications. The N-terminus is blocked.

Activity regulation. Inhibited by 2,4-dinitrophenyl-2-fluoro-2-deoxy-beta-D-glucopyranoside. Inhibited by sodium taurocholate. Inhibited by alpha-1-C-nonyl-DIX/AnDIX. The glucosylceramidase activity is slightly inhibited by conduritol B epoxide/CBE while the galactosylceramidase activity is not.

Polymorphism. The sequence shown in this entry differs from the translation of the reference genome assembly (GRCh38/hg38) due to a nonsense variant creating stop codon at position 456 in the reference genome, leading to the synthesis of a truncated protein lacking enzymatic activity in vitro. The sequence shown in this entry is that of variant p.Ter456Tyr, which has a frequency of about 88% in the human population according to the Genome Aggregation Database (gnomAD v3.1.2) and gives rise to a fully active beta-glucosidase.

Similarity. Belongs to the glycosyl hydrolase 1 family. Klotho subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H227-1	1	yes
Q9H227-2	2

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001360	Glyco_hydro_1	Family
IPR017853	GH_hydrolase_sf	Homologous_superfamily
IPR033132	GH_1_N_CS	Conserved_site

Pfam: PF00232

Enzyme classification (BRENDA):

• EC 3.2.1.21 — beta-glucosidase (BRENDA: 355 organisms, 1036 substrates, 816 inhibitors, 1052 Km, 608 kcat entries)

Substrate kinetics (BRENDA)

188 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
CELLOBIOSE	0.002–200	149
4-NITROPHENYL BETA-D-GLUCOPYRANOSIDE	0.006–68	134
4-NITROPHENYL-BETA-D-GLUCOPYRANOSIDE	0.001–10.34	121
P-NITROPHENYL-BETA-D-GLUCOPYRANOSIDE	0.007–12	34
2-NITROPHENYL BETA-D-GLUCOPYRANOSIDE	0.023–6.6	33
DHURRIN	0.031–2	24
SALICIN	0.12–37.14	24
4-NITROPHENYL BETA-D-GLUCOSIDE	0.114–6.09	19
4-NITROPHENYL-BETA-D-FUCOSIDE	0.12–2.7	19
GENTIOBIOSE	0.21–100	18
4-NITROPHENYL-BETA-D-GALACTOSIDE	0.11–16.6	15
4-NITROPHENYL BETA-D-FUCOPYRANOSIDE	0.14–5	14
4-NITROPHENYL-BETA-D-GALACTOPYRANOSIDE	0.23–10.2	13
4-NITROPHENYL BETA-D-GALACTOPYRANOSIDE	0.64–17.6	12
CELLOTRIOSE	0.0468–39	12

Catalyzed reactions (Rhea), 7 shown:

• a beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine + H2O = an N-acylsphing-4-enine + D-glucose (RHEA:13269)
• a beta-D-galactosyl-(1<->1’)-N-acylsphing-4-enine + H2O = an N-acylsphing-4-enine + D-galactose (RHEA:14297)
• beta-D-galactosyl-(1<->1)-sphing-4-enine + H2O = sphing-4-enine + D-galactose (RHEA:43908)
• beta-D-glucosyl-(1<->1)-N-octadecanoylsphing-4-enine + H2O = N-octadecanoylsphing-4-enine + D-glucose (RHEA:59284)
• beta-D-glucosyl-(1<->1)-sphing-4-enine + H2O = sphing-4-enine + D-glucose (RHEA:59288)
• beta-D-galactosyl-(1<->1’)-N-octadecanoylsphing-4-enine + H2O = N-octadecanoylsphing-4-enine + D-galactose (RHEA:59292)
• a beta-D-xylosyl-(1<->1’)-N-acylsphing-4-enine + cholesterol = cholesteryl 3-beta-D-xyloside + an N-acylsphing-4-enine (RHEA:70239)

UniProt features (68 total): helix 22, strand 16, mutagenesis site 7, binding site 6, sequence variant 5, sequence conflict 5, turn 3, active site 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
2E9L	X-RAY DIFFRACTION	1.6
2E9M	X-RAY DIFFRACTION	1.8
2ZOX	X-RAY DIFFRACTION	1.9
3VKK	X-RAY DIFFRACTION	2
2JFE	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H227-F1	97.30	0.97

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 165 (proton donor); 373 (nucleophile)

Ligand- & substrate-binding residues (6): 17; 120; 164; 309; 417; 424–425

Mutagenesis-validated functional residues (7):

Position	Phenotype
165	2-fold decreased glucosylceramidase activity.
165	loss of glucosylceramidase activity.
168	no change in temperature or ph dependence. decreased glucosidase activity.
225	decreased glucosidase activity.
308	decreased glucosidase activity.
373	2-fold decreased glucosylceramidase activity.
373	loss of glucosylceramidase activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9840310	Glycosphingolipid catabolism

MSigDB gene sets: 64 (showing top): GOBP_CERAMIDE_CATABOLIC_PROCESS, GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_OLIGOSACCHARIDE_CATABOLIC_PROCESS, GOBP_MEMBRANE_LIPID_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_GLYCOLIPID_CATABOLIC_PROCESS, GOBP_SPHINGOLIPID_METABOLIC_PROCESS, GOBP_AMIDE_METABOLIC_PROCESS, GOBP_PROTEIN_STABILIZATION, CAIRO_HEPATOBLASTOMA_DN, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, ZHAN_MULTIPLE_MYELOMA_HP_UP, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_LIPID_METABOLIC_PROCESS

GO Biological Process (8): glucosylceramide catabolic process (GO:0006680), galactosylceramide catabolic process (GO:0006683), oligosaccharide catabolic process (GO:0009313), glycoside catabolic process (GO:0016139), glycosylceramide catabolic process (GO:0046477), glycosphingolipid catabolic process (GO:0046479), protein stabilization (GO:0050821), beta-glucoside catabolic process (GO:1901805)

GO Molecular Function (5): galactosylceramidase activity (GO:0004336), glucosylceramidase activity (GO:0004348), beta-galactosidase activity (GO:0004565), beta-glucosidase activity (GO:0008422), glycosylceramidase activity (GO:0017042)

GO Cellular Component (3): cytosol (GO:0005829), membrane (GO:0016020), catalytic complex (GO:1902494)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycosphingolipid metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycosylceramide catabolic process	2
glycosylceramidase activity	2
cellular anatomical structure	2
glucosylceramide metabolic process	1
galactosylceramide metabolic process	1
galactolipid catabolic process	1
oligosaccharide metabolic process	1
carbohydrate catabolic process	1
glycoside metabolic process	1
glycosyl compound catabolic process	1
glycosylceramide metabolic process	1
glycosphingolipid catabolic process	1
ceramide catabolic process	1
glycosphingolipid metabolic process	1
glycolipid catabolic process	1
sphingolipid catabolic process	1
regulation of protein stability	1
glycoside catabolic process	1
galactosidase activity	1
glucosidase activity	1
hydrolase activity, hydrolyzing O-glycosyl compounds	1
cytoplasm	1
protein-containing complex	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

4 interactions, top by confidence:

A	B	Type	Score
PDCL3	GBA3	psi-mi:“MI:0915”(physical association)	0.400
GBA3	PRKCSH	psi-mi:“MI:0915”(physical association)	0.370
GBA3	DIRAS1	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): GBA3 (Two-hybrid), GBA3 (Affinity Capture-MS), GBA3 (Affinity Capture-MS), GBA3 (Affinity Capture-MS), CCT2 (Affinity Capture-MS), CCT4 (Affinity Capture-MS), DIRAS1 (Affinity Capture-MS), PDCL (Affinity Capture-MS), RAP1GDS1 (Affinity Capture-MS), GLG1 (Cross-Linking-MS (XL-MS)), PRKCSH (Two-hybrid)

ESM2 similar proteins: A0AAW1I778, A2SY66, A3BMZ5, A3C053, B7F8N7, B8AVF0, B9FHH2, E3W9M3, O64879, O64882, P26205, P97265, Q0DA21, Q0J0G1, Q0J0N4, Q2QSR8, Q339X2, Q3ECS3, Q5JK35, Q5N863, Q5RF65, Q5Z9Z0, Q682B4, Q75W17, Q7F9K4, Q7XKV2, Q7XKV4, Q7XKV5, Q7XPY7, Q7XSK0, Q84YK7, Q8GRX1, Q8GU20, Q8L7J2, Q8RZL1, Q95X01, Q9FH03, Q9FIU7, Q9FIW4, Q9FLU8

Diamond homologs: A2SY66, A3BMZ5, A3RF67, A5IUX8, A6U3R9, A7X569, B6ZKM3, B6ZKM4, B6ZKN1, B8AVF0, B9K7M5, C7N8L9, D5MTF8, E4Q361, O05508, O48779, O64879, O64883, O80690, P09848, P09849, P0C946, P10482, P12614, P22073, P22505, P26208, P38645, P42403, P67767, P94248, P97265, Q00326, Q02401, Q03506, Q08638, Q0DA21, Q0J0G2, Q0J0N4, Q1XH04

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	65
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1565 predictions. Top by Δscore:

Variant	Effect	Δscore
4:22735977:TCA:T	acceptor_loss	1.0000
4:22735980:G:GT	acceptor_loss	1.0000
4:22735980:GGA:G	acceptor_gain	1.0000
4:22748063:G:T	donor_gain	1.0000
4:22748831:TTTTA:T	acceptor_loss	1.0000
4:22748832:TTTA:T	acceptor_loss	1.0000
4:22748833:TTAG:T	acceptor_loss	1.0000
4:22748834:TA:T	acceptor_loss	1.0000
4:22748835:A:AG	acceptor_gain	1.0000
4:22748835:AGGAT:A	acceptor_loss	1.0000
4:22748836:G:GA	acceptor_loss	1.0000
4:22748836:G:GG	acceptor_gain	1.0000
4:22748923:G:GT	donor_gain	1.0000
4:22748948:G:GT	donor_gain	1.0000
4:22803295:GCCTA:G	donor_gain	1.0000
4:22693071:AAGG:A	donor_loss	0.9900
4:22693072:AGGTA:A	donor_loss	0.9900
4:22693074:G:C	donor_loss	0.9900
4:22693075:T:G	donor_loss	0.9900
4:22710282:G:GG	donor_gain	0.9900
4:22735979:A:AG	acceptor_gain	0.9900
4:22735979:AGGAG:A	acceptor_gain	0.9900
4:22735980:G:GG	acceptor_gain	0.9900
4:22735980:GGAGG:G	acceptor_gain	0.9900
4:22736103:G:GT	donor_gain	0.9900
4:22736160:T:A	acceptor_gain	0.9900
4:22748063:G:GT	donor_gain	0.9900
4:22748835:AG:A	acceptor_gain	0.9900
4:22748836:GG:G	acceptor_gain	0.9900
4:22748836:GGAT:G	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS10000431 (4:22784411 T>C), RS1000048890 (4:22729596 C>T), RS1000068155 (4:22802848 A>C), RS1000079017 (4:22739911 C>T), RS1000093634 (4:22778684 C>T), RS1000110695 (4:22698195 G>T), RS1000121190 (4:22695526 G>A), RS1000125196 (4:22802721 A>G,T), RS1000142216 (4:22712461 T>G), RS1000155866 (4:22778771 T>A), RS1000225757 (4:22772793 A>C,G), RS1000231772 (4:22720931 C>G,T), RS1000233173 (4:22812743 G>A), RS1000262062 (4:22727214 A>G), RS1000328718 (4:22755082 T>TG)

Disease associations

OMIM: gene MIM:606619 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST002682_6	Tourette’s syndrome or obsessive-compulsive disorder	9.000000e-06
GCST002932_8	Manganese levels	6.000000e-06
GCST003152_3	White matter lesion progression (adjusted for white matter lesion burden at baseline)	2.000000e-06
GCST005025_6	Anti-saccade response	2.000000e-06
GCST005790_91	Rosacea symptom severity	4.000000e-06
GCST005926_1	Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma	8.000000e-07
GCST006249_42	Serum metabolite levels	3.000000e-17
GCST007844_6	Ankylosing spondylitis	7.000000e-06
GCST009391_974	Metabolite levels	6.000000e-07
GCST009391_990	Metabolite levels	4.000000e-06
GCST009733_234	Urinary metabolite levels in chronic kidney disease	1.000000e-30
GCST009733_52	Urinary metabolite levels in chronic kidney disease	2.000000e-27
GCST009733_53	Urinary metabolite levels in chronic kidney disease	2.000000e-14
GCST009733_54	Urinary metabolite levels in chronic kidney disease	2.000000e-38
GCST009735_42	Urinary metabolite modules (eigenmetabolites) in chronic kidney disease	2.000000e-30
GCST011983_5	Fasting glucose	7.000000e-07
GCST012020_99	Serum metabolite levels	2.000000e-27

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007746	white matter lesion progression measurement
EFO:0006874	antisaccade response measurement
EFO:0009180	rosacea severity measurement
EFO:0005843	cortisol measurement
EFO:0009175	response to synacthen
EFO:0010538	taurocholate measurement
EFO:0010475	deoxycholate measurement
EFO:0005116	urinary metabolite measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3865 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 4,739 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL307429	DUVOGLUSTAT	2	4,739

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 4 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.70	IC50	2000	nM	CHEMBL2029773

PubChem BioAssay actives

1 with measured affinity, of 63 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R,3S,4S,5R)-2-(2-octylsulfanylethyl)piperidine-3,4,5-triol;hydrochloride	662919: Inhibition of human cytosolic beta-glucosidase using 4-methylumbelliferyl beta-D-glucopyranoside as substrate after 15 mins by fluorimetric analysis	ic50	2.0000	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	affects expression, decreases expression, decreases methylation	4
sodium arsenite	decreases expression, increases expression	2
Acetaminophen	affects cotreatment, decreases expression	2
Benzo(a)pyrene	decreases expression, increases methylation, affects methylation	2
Valproic Acid	decreases methylation, increases expression	2
Cyclosporine	decreases expression	2
methyleugenol	decreases expression	1
propionaldehyde	decreases expression	1
bisphenol A	affects methylation	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
pentanal	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
belinostat	decreases expression	1
Rosiglitazone	decreases expression	1
Troglitazone	decreases expression	1
Aldehydes	decreases expression	1
Chenodeoxycholic Acid	decreases expression, affects cotreatment	1
Deoxycholic Acid	decreases expression, affects cotreatment	1
Estradiol	decreases expression	1
Glycochenodeoxycholic Acid	affects cotreatment, decreases expression	1
Glycocholic Acid	affects cotreatment, decreases expression	1
Glycodeoxycholic Acid	affects cotreatment, decreases expression	1
Lipopolysaccharides	affects response to substance, affects cotreatment, increases expression	1
Methapyrilene	increases methylation	1
Silicon Dioxide	decreases expression	1
Tartrazine	affects cotreatment, decreases expression	1

ChEMBL screening assays

14 unique, capped per target: 14 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1007694	Binding	Inhibition of beta-glucosidase	Iminosugar-producing Thai medicinal plants. — J Nat Prod

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.